Hematologic Neoplasms: Clinical Trials

56 trials for Hematologic Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

56 completed. 56 Phase 3, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 356Completed 56
Phase 27Completed 7

Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms

Trials (filtered) newest first · largest first

All 56 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate P1101 in Japanese PV Patients
P1101, Low-dose aspirin, Phlebotomy - Polycythemia Vera (PV)
Phase 3CompletedPharmaEssentia Japan K.K.212023-10-172024-11-08
Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT
PBSCs, Cord, BMSCs - Hematological Malignancies, Hematopoietic Stem Cell Transplantation
Phase 3CompletedNanfang Hospital, Southern Medical University3142022-02-152024-08-13
Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy
Placebo Administration, Questionnaire Administration, Rose Geranium in Sesame Oil Nasal Spray - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Phase 3CompletedMayo Clinic1062020-11-132025-12-03
Self-Management Program and Survivorship Care Plan in Improving the Health of Cancer Survivors After Stem Cell Transplant
Best Practice and Internet site with links to existing resources, Internet, Mobile app and Telehealth Intervention, Survey Administration - Hematopoietic and Lymphoid Cell Neoplasm
Phase 3CompletedFred Hutchinson Cancer Center5462020-10-292025-01-29
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
omidubicel - Hematological Malignancies
Phase 3CompletedGamida Cell ltd362020-07-082026-06-22
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Carfilzomib, Lenalidomide, Dexamethasone - Relapsed or Refractory Multiple Myeloma
Phase 3CompletedAmgen4542019-05-082024-08-13
Expressive Helping for Stem Cell Transplant Patients
Expressive Helping, Factual Writing - Stem Cell Transplantation, Hematologic Malignancy
Phase 3CompletedNorthwestern University4052019-03-062023-05-06
Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH)
Virtual Reality, Kalinox - Hematologic Neoplasms
Phase 2 / Phase 3CompletedWeprom1262018-09-062020-06-23
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Apixaban - Cerebral Vein Thrombosis, Deep Vein Thrombosis
Phase 3CompletedAcademic and Community Cancer Research United3702017-07-142025-05-18
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
NiCord® (omidubicel), Cord Blood Unit - Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL)
Phase 3CompletedGamida Cell ltd1252016-12-162026-02-25
Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study
Tranexamic Acid - Hematologic Neoplasms
Phase 3CompletedOttawa Hospital Research Institute1002016-10-012020-05-18
Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation
Laser treatment, Placebo - Hematologic Malignancy
Phase 3CompletedInstitut de Cancérologie de la Loire2342016-06-272020-01-29
Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients
Allogeneic (Allo) hematopoietic stem cell transplantation - Hematologic Neoplasms
Phase 3CompletedInstitut Paoli-Calmettes1082016-02-232026-10-16
Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens
Olanzapine, Placebo - Complications of Bone Marrow Transplant, Hematologic Neoplasms
Phase 3CompletedAugusta University1082015-11-012018-08-20
Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT
Peg interferon alfa-2b - Hematological Neoplasms, Recurrence
Phase 2 / Phase 3CompletedShanghai General Hospital, Shanghai Jiao Tong University School of Medicine302015-08-012023-03-16
Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients
Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen - Polycythemia Vera
Phase 3CompletedAOP Orphan Pharmaceuticals AG302015-07-012016-02-17
TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia
Tranexamic acid (TXA)., Placebo - Hematologic Neoplasms, Hemorrhage
Phase 3CompletedNHS Blood and Transplant6162015-06-012025-10-28
Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
Ruxolitinib - Polycythemia Vera
Phase 3CompletedNovartis Pharmaceuticals1612014-11-212019-07-18
AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.
Pegylated-Proline-interferon alpha-2b, Best available therapy (BAT) - Polycythemia Vera
Phase 3CompletedAOP Orphan Pharmaceuticals AG1702014-11-012021-06-01
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant) - Hematopoietic/Lymphoid Cancer, Nausea and Vomiting
Phase 3CompletedAlliance for Clinical Trials in Oncology4012014-08-202025-01-28

Showing 20 of 56. Sign in to see all of them.

Narrower conditions

Polycythemia Vera (20)  ·  Myeloproliferative Disorders (14)  ·  Leukemia, Myeloid, Acute (13)  ·  Lymphoma, Large B-Cell, Diffuse (13)  ·  Multiple Myeloma (13)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (13)  ·  Hodgkin Disease (12)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (12)  ·  Lymphoma, Mantle-Cell (12)  ·  Thrombocythemia, Essential (12)  ·  Waldenstrom Macroglobulinemia (12)  ·  Leukemia, Myeloid, Chronic-Phase (11)  ·  Lymphoma, Non-Hodgkin (11)  ·  Myelodysplastic Syndromes (11)

Broader conditions

Hemic and Lymphatic Diseases (56)  ·  Neoplasms by Site (56)  ·  Hematologic Diseases (51)  ·  Neoplasms (50)  ·  Bone Marrow Diseases (23)  ·  Pathological Conditions, Signs and Symptoms (21)  ·  Bone Marrow Neoplasms (20)  ·  Pathologic Processes (20)  ·  Neoplasms by Histologic Type (19)  ·  Immune System Diseases (18)  ·  Disease Attributes (17)  ·  Immunoproliferative Disorders (17)  ·  Hemorrhagic Disorders (16)  ·  Cardiovascular Diseases (15)

Interventions

Hydroxyurea (5)  ·  ruxolitinib (4)  ·  Voriconazole (3)  ·  Whole-Body Irradiation (3)  ·  fludarabine phosphate (3)  ·  peginterferon alfa-2b (3)  ·  Aspirin (2)  ·  Caspofungin (2)  ·  Cyclophosphamide (2)  ·  Cyclosporine (2)  ·  Cyclosporins (2)  ·  Early Intervention, Educational (2)  ·  Lenalidomide (2)  ·  Mycophenolic Acid (2)  ·  Olanzapine (2)

Sponsors

Fred Hutchinson Cancer Center (4)  ·  Novartis Pharmaceuticals (4)  ·  AOP Orphan Pharmaceuticals AG (3)  ·  Alliance for Clinical Trials in Oncology (3)  ·  M.D. Anderson Cancer Center (3)  ·  Memorial Sloan Kettering Cancer Center (3)  ·  Amgen (2)  ·  Gamida Cell ltd (2)  ·  Incyte Corporation (2)  ·  Ottawa Hospital Research Institute (2)  ·  Academic and Community Cancer Research United (1)  ·  Augusta University (1)  ·  Azienda Ospedaliera San Giovanni Battista (1)  ·  Case Comprehensive Cancer Center (1)  ·  Children's Oncology Group (1)

Countries

United States (35)  ·  France (16)  ·  Germany (13)  ·  Italy (13)  ·  Spain (12)  ·  Canada (11)  ·  Hungary (10)  ·  Austria (8)  ·  Belgium (8)  ·  Czechia (8)  ·  Slovakia (8)  ·  Russia (7)  ·  Turkey (Türkiye) (7)  ·  United Kingdom (7)  ·  Bulgaria (6)

Top investigators

Heinz Gisslinger, MD (3)  ·  Brenda Sandmaier (2)  ·  Mitchell Horwitz, MD (2)  ·  Agha Mounzer, MD (1)  ·  Alan Tinmouth, MD MSc (1)  ·  Alberto Bosi, MD (1)  ·  Amber B Clemmons, PharmD (1)  ·  Bernard DePrijck, MD (1)  ·  Celia Grosskreutz, MD (1)  ·  Charles L Loprinzi (1)  ·  Christelle Ferra, MD (1)  ·  Christopher C Dvorak (1)  ·  Chun Wang, M.D., Ph.D. (1)

Results publications

PMID 29396713, PMID 32499241, PMID 41890273, PMID 15459300, PMID 17397698, PMID 20525993, PMID 21467546, PMID 21856226, PMID 22207416, PMID 22480131, PMID 22814329, PMID 23109697, PMID 23502220, PMID 24335106, PMID 24532039, PMID 25478136, PMID 25629741, PMID 25961767, PMID 26700120, PMID 26700123, PMID 27020837, PMID 27102499, PMID 27410922, PMID 27798034, PMID 27916398, PMID 28193568, PMID 29253068, PMID 29477778, PMID 29906570, PMID 30287855, PMID 31248843, PMID 31399378, PMID 31515250, PMID 31606897, PMID 31615553, PMID 31982039, PMID 32083994, PMID 32665955, PMID 32781287, PMID 33136159, PMID 33811823, PMID 34157093, PMID 34670600, PMID 34932836, PMID 35007321, PMID 35597252, PMID 35662590, PMID 36642232, PMID 36790852, PMID 36999619

NIH funding

2014 (3), P30CA015704 (2), 2008 (1), P01CA018029 (1), P01CA078902 (1), P01CA108671 (1), P30CA015083 (1), P30CA068485 (1), R01CA126971 (1), R01CA127655 (1), R01CA160684 (1), R01CA215134 (1), R01CA223963 (1), U10CA031946 (1), U10CA095861 (1)